Teva Pharmaceuticals Industries Limited (NYSE:TEVA) is a global leader in developing, manufacturing, and distributing generic drugs, with a portfolio of over 3,500 products across various therapeutic ...

Teva's business is encountering headwinds, including declining U.S. generics revenue. Read what this biotech plans to do in ...

Teva Pharmaceutical Industries Ltd. failed to convince the Federal Circuit to reconsider a December ruling that five patents ...

Teva is looking to evolve its business through new R&D programmes and development of 'New Therapeutic Entities' from off-patent drugs. Andrew McConaghie speaks to the company's Richard Malamut ...

Mylan's settlement with drug wholesalers comes on the heels of the company reaching a $264 million settlement for consumers ...

The Federal Circuit’s refusal to reconsider its ruling forcing Teva to delist asthma-inhaler patents from the FDA’s Orange ...

With a strong presence in North America, Europe, Israel, and beyond, Teva offers a wide range of medications, including treatments for central nervous system disorders, respiratory conditions ...

He did not give specific figures. Teva last month reported a slightly larger than expected rise in fourth-quarter profit. Francis said its trio of branded drugs to treat migraines, Huntington's ...

(Reuters) -All drug manufacturers, including Novo Nordisk and Teva Pharmaceuticals, whose medicines are part of the second ...

Francis has presented his strategic plan based on growth including an emphasis on Teva's branded drugs. "In 2023, the environment was challenging and that was the narrative. Two years later ...

Kerry Logistics Network Limited ('KLN'; Stock Code 0636.HK), through its subsidiary, Kerry Pharma, and Teva Pharmaceutical Hong Kong Limited ('Teva') entered into an exclusive agreement for ...